

Erlotinib SATURN

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE

OS



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects




Other adjustments



Erlotinib SATURN

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

1




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies  
Therapeutic Indication: Locally advanced or metastatic NSCLC with EGFR-activating mutations and stable disease after first-line ChT  
Experimental Arm: Erlotinib  
Control Arm: Placebo

